Medical Physics and Applied Sciences is a journal published Triannualy in English language. We welcome original research articles, review articles, editorials, case reports, and others from any part of the world. Manuscripts are reviewed by members of the international editorial board and our expert peer reviewers, then either accepted for publication or rejected by the chief editor. Shorter articles are particularly welcome.

New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients. In initial results from a multicentre trial assessing the impact of 18F-DCFPyL prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), a PET-directed change in management was observed in two-thirds of patients

Prostate cancer is the second most common cancer in men in the United States. According to the American Cancer Society, an estimated one in nine men will receive a prostate cancer diagnosis in his lifetime, and more than 191,000 men will be diagnosed with prostate cancer this year. Approximately 30 to 40 percent of men experience a biochemical recurrence of prostate cancer in which their prostate-specific antigen (PSA) levels rise after initial treatment.

DCFPyL (PSMA) PET/CT has been shown to be effective in diagnosing patients with prostate cancer. To assess its impact on the management of patients with suspected limited recurrent prostate cancer after primary therapy, researchers conducted a prospective, large-scale multicenter trial. The study included 410 men who had biochemical failure after primary therapy, had either no or limited disease on conventional imaging (CT and bone scintigraphy), and had undergone one of several prostate cancer treatments.

PSMA PET/CT identified disease in more than half of the men in whom CT and bone scan scintigraphy was negative. Additional sites of disease were observed in nearly two-thirds of patients in whom limited metastases were detected prior to PET. PSMA PET-directed management changes were recorded in 66 percent of the patients. The most common changes were conversion from observation or systemic therapy to surgery or radiation, or the addition of nodal-directed therapy to salvage surgery or radiation.

Evidence generated from this study will help in seeking regulatory approvals to make molecular imaging with 18F-DCFPyL widely available and will pave the way for clinical studies that incorporate PSMA PET as a treatment planning tool to assess ultimate impact on patient outcomes.

Authors are welcome to submit their manuscripts. Submit manuscript at https://www.scholarscentral.org/submission/insights-medical-physics.html (or) as an e-mail attachment to medicalsci@scholarlymed.com or medicalsci@medicinaljournals.com

Media contact

Eliza Miller

Managing Editor

Journal of Medical Physics and Applied Sciences